Core Viewpoint - CICC maintains a target price of HKD 8.9 for China Biologic Products (01177) and a "outperform industry" rating, with adjusted net profit forecasts for 2025 and 2026 remaining at RMB 4.47 billion and RMB 4.92 billion respectively, and introducing a forecast of RMB 5.42 billion for 2027 [1] Group 1 - The company announced a 100% acquisition of Hejia Bio for RMB 1.2 billion [1] - Hejia Bio focuses on the siRNA sector, particularly in the areas of weight loss metabolism, cardiovascular, and neurological diseases, with a core platform that has competitive advantages [1] - The existing therapies in the chronic disease field generally have limitations in efficacy, safety risks, and low patient compliance, indicating a significant unmet clinical need [1] Group 2 - The acquisition is expected to help China Biologic Products build a next-generation cardiovascular treatment innovation pipeline and enhance its layout in the weight loss metabolism field [1] - The company's established R&D system and sales channels are likely to facilitate the efficient clinical advancement and subsequent commercialization of Hejia Bio's products, leading to potential synergistic benefits for both parties [1]

Core Viewpoint - China National Pharmaceutical Group announced the acquisition of 100% of Hejia Bio for a consideration of 1.2 billion yuan, focusing on the siRNA sector and targeting chronic diseases in weight loss metabolism, cardiovascular, and nervous system areas [1] Group 1: Acquisition Details - The acquisition price for Hejia Bio is set at 1.2 billion yuan, which allows China National Pharmaceutical Group to enhance its capabilities in the siRNA field [1] - Hejia Bio has a differentiated competitive advantage with its core platform, which is expected to complement China National Pharmaceutical Group's existing portfolio [1] Group 2: Market Opportunity - The chronic disease sector faces significant unmet clinical needs due to limitations in existing therapies, safety risks, and low patient compliance [1] - The acquisition is anticipated to help China National Pharmaceutical Group build an innovative pipeline for next-generation cardiovascular treatments and improve its weight loss metabolism offerings [1] Group 3: Synergy and Growth Potential - The established R&D system and sales channels of China National Pharmaceutical Group are expected to facilitate the efficient clinical advancement and commercialization of Hejia Bio's products [1] - The collaboration between the two companies is projected to achieve synergistic benefits and mutual success [1] Group 4: Analyst Rating - The target price for China National Pharmaceutical Group is maintained at 8.9 HKD, with an "outperform" rating relative to the industry [1]